OBJECTIVE： To investigate clinical efficacy and toxic and side effects of bevacizumab combined with chemotherapy in the treatment of advanced gastric cancer. METHODS： 84 patients with advanced gastric cancer were randomly divided into combination group and chemotherapy group， with 42 cases in each group. Chemotherapy group received FOLFOX4 chemotherapy regimen （oxaliplatin+calcium folinate+fluorouracil）； combination group was additionally given bevacizumab 7.5 mg/kg intravenously， d1， on the basis of chemotherapy. A treatment course lasted for 21 d， and both groups received 3 courses of treatment. The short-term efficacy， the quality improvement of life， serum tumor marker before and after chemotherapy and the toxic and side effects were compared between 2 groups. RESULTS： The effective rate in combination group （57.14％） was significantly higher than chemotherapy group （35.71％）， improvement rate of life quality in combination group was higher than chemotherapy group， reduction rate of life quality in combination group was lower than chemotherapy group， the differences were statistically significant （P＜0.05）； after chemotherapy， the serum CEA and CA199 levels were significantly decreased in both groups， the decrease of combination group was more significant than that of chemotherapy， with statistical significance （P＜0.05）. The incidence of decrease in leucocytes， platelet and hemoglobin， periphery neurotoxicity， nausea and vomiting， liver and kidney function in combination group was higher than in chemotherapy， but there was no statistical significance （P＞0.05）. CONCLUSIONS： Bevacizumab combined with chemotherapy is effective in the treatment of advanced gastric cancer and don’t increase toxic and side effects.